Qiagen N.V.
QGEN
Classement en actions
#2056
Qiagen N.V. provides sample to insight solutions that transform biological... Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Prix de l'action
$48.85
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$10.07B
Changement (1 jour)
4.96%
Changement (1 an)
0.61%
Pays
NL
Échange Qiagen N.V. (QGEN)
Catégorie
Healthcare
Ratio P/E pour Qiagen N.V. (QGEN)
Ratio P/E au October 2026 TTM : 23.36
Selon les derniers rapports financiers et le cours de l'action de Qiagen N.V., le ratio P/E actuel (TTM) est de 23.36. À la fin de l’année 2024, le P/E de l’entreprise était de 118.59.
Historique du ratio P/E pour Qiagen N.V. de 2000 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 23.36 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 118.59 | 304.12% |
| 2023 | 29.34 | 6.39% |
| 2022 | 27.58 | 8.47% |
| 2021 | 25.43 | -26.45% |
| 2020 | 34.57 | -118.18% |
| 2019 | -190.18 | -539.51% |
| 2018 | 43.27 | -76.64% |
| 2017 | 185.20 | 113.69% |
| 2016 | 86.66 | 65.09% |
| 2015 | 52.50 | 5.85% |
| 2014 | 49.60 | -41.99% |
| 2013 | 85.50 | 145.24% |
| 2012 | 34.86 | -2.40% |
| 2011 | 35.72 | 6.66% |
| 2010 | 33.49 | -5.84% |
| 2009 | 35.57 | -13.60% |
| 2008 | 41.17 | -45.13% |
| 2007 | 75.02 | 120.64% |
| 2006 | 34.00 | 14.85% |
| 2005 | 29.60 | -15.34% |
| 2004 | 34.97 | -18.98% |
| 2003 | 43.16 | 25.46% |
| 2002 | 34.40 | -57.92% |
| 2001 | 81.75 | -67.43% |
| 2000 | 250.99 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 36.15 | 54.74% |
US
|
|
| 39.77 | 70.23% |
US
|
|
| -290.26 | -1,342.32% |
US
|
|
| - | - |
CN
|
|
| 34.18 | 46.31% |
US
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.